Lipocine has begun dosing participants in BLOOM, a new Phase 3 trial of LPCN 1154, its investigational oral treatment for postpartum depression. The company is developing the drug as a 48-hour course intended for use at home; BLOOM is designed to add clinical evidence toward a potential regulatory application.
The new study follows a prior Phase 3 trial that did not meet its primary efficacy endpoint in the full analysis set. Lipocine says BLOOM incorporates changes to site selection, assessments and data-quality controls, while retaining the same dosing regimen and primary endpoint.
Key details
- Study size and timing: BLOOM is expected to enroll about 120 participants. Lipocine expects topline results in the second half of 2027.
- Design: The placebo-controlled outpatient study will evaluate LPCN 1154’s efficacy and safety. Its primary endpoint is the change in participants’ 17-item Hamilton Depression Rating Scale score from baseline to 60 hours after dosing begins.
- Changes to study operations: Lipocine plans to use third-party support in selecting sites, include geographically diverse and academic sites, limit enrollment at individual sites and periodically review site populations. Sites with significant operational or data-quality concerns will not be selected.
- Measures aimed at reducing placebo response: The protocol uses fewer rating scales and assessments, less contact between participants and site staff, centralized screening and eligibility ratings, and standardized education about study procedures.
- Planned analyses: Prespecified sensitivity analyses will assess the effect of outlier sites and examine pharmacokinetic data to help evaluate the robustness of the findings.
- Prior trial context: Safety outcomes and exploratory post hoc findings from the earlier Phase 3 study support further evaluation, but that trial missed its primary endpoint in the full analysis set. The changes in BLOOM are intended to improve execution and make results easier to interpret; they do not establish that the treatment works.
- Regulatory status: LPCN 1154 is an investigational oral formulation of brexanolone and is not FDA-approved. Lipocine says the study is intended to complement its existing clinical data for a potential application through the 505(b)(2) pathway.
BLOOM is therefore a renewed clinical test of the same treatment regimen and primary endpoint after a prior efficacy setback. Its planned design changes address study execution and data quality, while the central question—whether LPCN 1154 improves depression symptoms versus placebo—remains to be answered.